PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

NPM-ALK induces reprogramming of mature TCR-stimulated T cells resulting in de-differentiation and malignant transformation

(2021) Jan M. Pawlicki et al.   CANCER RESEARCH

Immune Checkpoint Inhibitors in Prostate Cancer

(2021) Shobi Venkatachalam et al.   Cancers

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

(2021) Nicholas A. Vitanza et al.   NATURE MEDICINE

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

(2021) Prasad S Adusumilli et al.   Cancer Discovery

Multiplex digital spatial profiling of proteins and RNA in fixed tissue

(2020) Christopher R. Merritt et al.   NATURE BIOTECHNOLOGY

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

(2020) Kurt A. Schalper et al.   NATURE MEDICINE

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

(2020) Kobe C. Yuen et al.   NATURE MEDICINE

Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

(2020) Johanna Theruvath et al.   NATURE MEDICINE

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings

(2020) Felipe de Galiza Barbosa et al.   CANCER IMAGING

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

(2020) Tanja Stüber et al.   Journal for ImmunoTherapy of Cancer

GLCCI1 is a novel protector against glucocorticoid-induced apoptosis in T cells

(2019) Zentaro Kiuchi et al.   FASEB JOURNAL

The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells

(2019) Alexandre V. Hirayama et al.   BLOOD

Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice

(2019) Matthias Mulazzani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration

(2019) Christopher L. Nobles et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

(2018) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma

(2018) Christine E. Brown et al.   MOLECULAR THERAPY

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium

(2018) Andrew R. Medvec et al.   Molecular Therapy-Methods & Clinical Development

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

(2018) Joseph A. Fraietta et al.   NATURE

Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores

(2018) Thomas Gevaert et al.   Scientific Reports

Effective combinatorial immunotherapy for castration-resistant prostate cancer

(2017) Xin Lu et al.   NATURE

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma

(2017) Mozhdeh Foroozan et al.   PATHOLOGY RESEARCH AND PRACTICE

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

(2016) Zuguang Gu et al.   BIOINFORMATICS

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

(2016) Joseph A. Fraietta et al.   BLOOD

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

(2016) Cameron J. Turtle et al.   Science Translational Medicine

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma

(2015) Ritsuko Nakamura et al.   CANCER SCIENCE

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients

(2015) D. M. S. Hossain et al.   CLINICAL CANCER RESEARCH

Fitting Linear Mixed-Effects Models Usinglme4

(2015) Douglas Bates et al.   Journal of Statistical Software

Comparing DNA integration site clusters with scan statistics

(2014) Charles C. Berry et al.   BIOINFORMATICS

Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

(2014) E. Basch et al.   JNCI-Journal of the National Cancer Institute

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Easy quantitative assessment of genome editing by sequence trace decomposition

(2014) Eva K. Brinkman et al.   NUCLEIC ACIDS RESEARCH

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens

(2014) Harm Westdorp et al.   Frontiers in Immunology

Blockade of TGF-  Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer

(2013) G. M. Bendle et al.   JOURNAL OF IMMUNOLOGY

Truncated Form of TGF- RII, But Not Its Absence, Induces Memory CD8+ T Cell Expansion and Lymphoproliferative Disorder in Mice

(2013) H. Ishigame et al.   JOURNAL OF IMMUNOLOGY

Estimating abundances of retroviral insertion sites from DNA fragment length data

(2012) Charles C. Berry et al.   BIOINFORMATICS

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

(2012) L Zhang et al.   GENE THERAPY

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

(2012) J. Scholler et al.   Science Translational Medicine

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

A method to sequence and quantify DNA integration for monitoring outcome in gene therapy

(2011) Troy Brady et al.   NUCLEIC ACIDS RESEARCH

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Preclinical Evaluation of a Recombinant Anti-Prostate Specific Membrane Antigen Single-Chain Immunotoxin Against Prostate Cancer

(2010) Philipp Wolf et al.   JOURNAL OF IMMUNOTHERAPY

Immunosuppressive CD14+HLA-DRlow/−monocytes in prostate cancer

(2009) Stanimir Vuk-Pavlović et al.   PROSTATE

Empirical Evaluation of a New Method for Calculating Signal-to-Noise Ratio for Microarray Data Analysis

(2008) Z. He et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor

(2008) Aaron E. Foster et al.   JOURNAL OF IMMUNOTHERAPY